{"filing":{"accession_number":"0001104659-26-075720","cik":"0001888886","ticker":"GPCR","company_name":"Structure Therapeutics Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618249d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926075720/tm2618249d1_8k.htm"},"events":[{"id":11808,"run_id":10386,"accession_number":"0001104659-26-075720","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This 8-K Item 5.07 discloses the results of Structure Therapeutics' 2026 Annual General Meeting of Shareholders held on June 17, 2026, including voting outcomes for three proposals: election of three Class III directors (Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure of shareholder vote results at an annual meeting is a material event affecting investor understanding of corporate governance and board composition.","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8490,"accession_number":"0001104659-26-075720","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Structure Therapeutics' 2026 Annual General Meeting of Shareholders held on June 17, 2026, including voting outcomes for three proposals: election of three Class III directors (Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure of shareholder vote results at an annual meeting is a material event affecting investor understanding of corporate governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:07:41.309908+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8490,"accession_number":"0001104659-26-075720","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Structure Therapeutics' 2026 Annual General Meeting of Shareholders held on June 17, 2026, including voting outcomes for three proposals: election of three Class III directors (Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch), ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure of shareholder vote results at an annual meeting is a material event affecting investor understanding of corporate governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T20:07:41.309908+00:00","company_name":"Structure Therapeutics Inc.","ticker":"GPCR","filing_date":"2026-06-18"}]}